Enterprise Value

251.7M

Cash

182M

Avg Qtr Burn

-18.19M

Short % of Float

32.79%

Insider Ownership

0.78%

Institutional Own.

63.43%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
metabolic dysfunction-associated steatohepatitis

Phase 2b

Data readout

Pemvidutide (ALT-801) (GLP-1R/GCGR) Details
Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease

Big Mover™

Susp. Mover™

Phase 2b

Data readout

Phase 2

Update

Phase 1b

Update

Failed

Discontinued

Failed

Discontinued

NasoShield (Vaccine) Details
Anthrax, Bacterial infection

Failed

Discontinued

Failed

Discontinued

HepTCell Details
Chronic hepatitis B

Failed

Discontinued